Development Level

Tbio 105 | 10,625
Tchem 43 | 1,890
Tclin 40 | 602
Tdark 9 | 7,003

Collection

Ion Channel: IDG Consortium (Targets) 27 | 102
Kinase: IDG Consortium (Complete/Control) 1 | 37

IMPC Phenotype

preweaning lethality, complete... 7 | 633
abnormal behavior 4 | 226
decreased body weight 3 | 174
embryonic lethality prior to t... 3 | 187
hyperactivity 3 | 108
increased circulating sodium l... 3 | 71
abnormal embryo size 2 | 112
abnormal epididymis morphology 2 | 31
abnormal retina morphology 2 | 100
abnormal vibrissa morphology 2 | 17
decreased circulating HDL chol... 2 | 77
decreased circulating amylase ... 2 | 24
decreased circulating calcium ... 2 | 33
decreased circulating choleste... 2 | 85
decreased lean body mass 2 | 195
decreased total body fat amoun... 2 | 186
enlarged epididymis 2 | 27
impaired glucose tolerance 2 | 52
increased bone mineral content 2 | 92
increased circulating chloride... 2 | 43
increased startle reflex 2 | 38
preweaning lethality, incomple... 2 | 260
abnormal behavioral response t... 1 | 52
abnormal bone structure 1 | 131
abnormal cornea morphology 1 | 24
abnormal eye morphology 1 | 38
abnormal eye size 1 | 11
abnormal facial morphology 1 | 9
abnormal forebrain development 1 | 18
abnormal head morphology 1 | 10
abnormal hindbrain development 1 | 24
abnormal lens morphology 1 | 73
abnormal maxilla morphology 1 | 16
abnormal midbrain development 1 | 22
abnormal neural tube closure 1 | 37
abnormal placenta vasculature 1 | 2
abnormal response to new envir... 1 | 8
abnormal response to tactile s... 1 | 16
abnormal retinal pigmentation 1 | 61
abnormal seminal vesicle morph... 1 | 47
abnormal sensory capabilities-... 1 | 3
abnormal sleep behavior 1 | 63
abnormal snout morphology 1 | 18
abnormal startle reflex 1 | 14
abnormal tooth morphology 1 | 24
absent vibrissae 1 | 14
cyanosis 1 | 6
decreased Ly6C low monocyte nu... 1 | 23
decreased bone mineral content 1 | 157
decreased circulating LDL chol... 1 | 37
decreased circulating alkaline... 1 | 41
decreased circulating bilirubi... 1 | 14
decreased circulating free fat... 1 | 39
decreased circulating fructosa... 1 | 31
decreased circulating glucose ... 1 | 121
decreased circulating iron lev... 1 | 25
decreased circulating serum al... 1 | 79
decreased circulating total pr... 1 | 41
decreased eosinophil cell numb... 1 | 41
decreased erythrocyte cell num... 1 | 43
decreased fasted circulating g... 1 | 49
decreased lumbar vertebrae num... 1 | 62
decreased prepulse inhibition 1 | 52
decreased respiratory quotient 1 | 12
edema 1 | 11
hemorrhage 1 | 12
increased blood uric acid leve... 1 | 5
increased body weight 1 | 42
increased caudal vertebrae num... 1 | 8
increased circulating alkaline... 1 | 119
increased circulating fructosa... 1 | 11
increased circulating iron lev... 1 | 25
increased circulating magnesiu... 1 | 10
increased effector memory CD4-... 1 | 15
increased granulocyte number 1 | 8
increased heart weight 1 | 37
increased hematocrit 1 | 36
increased kidney weight 1 | 4
increased leukocyte cell numbe... 1 | 37
increased mean corpuscular vol... 1 | 91
increased mean platelet volume 1 | 19
increased or absent threshold ... 1 | 128
increased plasma cell number 1 | 5
prenatal lethality 1 | 16
respiratory system phenotype 1 | 2
short tibia 1 | 82
small epididymis 1 | 3

Disease

medulloblastoma, large-cell 96 | 6,234
glioblastoma 91 | 5,572
psoriasis 90 | 6,685
ovarian cancer 82 | 8,491
osteosarcoma 79 | 7,933
atypical teratoid / rhabdoid tumor 74 | 4,369
pilocytic astrocytoma 64 | 3,086
lung cancer 59 | 4,473
primitive neuroectodermal tumor 59 | 3,031
oligodendroglioma 53 | 2,849
lung carcinoma 52 | 2,844
Carcinoma 51 | 2,147
subependymal giant cell astrocytoma 48 | 2,287
lung adenocarcinoma 47 | 2,714
pediatric high grade glioma 47 | 2,712
invasive ductal carcinoma 45 | 2,950
ependymoma 44 | 2,514
Breast cancer 43 | 3,098
intraductal papillary-mucinous neoplasm (IPMN) 43 | 3,289
malignant mesothelioma 42 | 3,163
intraductal papillary-mucinous adenoma (IPMA) 41 | 2,956
Pick disease 40 | 1,893
colon cancer 40 | 1,475
intraductal papillary-mucinous carcinoma (IPMC) 40 | 2,988
pituitary cancer 40 | 1,972
astrocytic glioma 38 | 2,241
adult high grade glioma 35 | 2,148
posterior fossa group A ependymoma 33 | 1,511
Atrial Fibrillation 31 | 110
acute quadriplegic myopathy 31 | 1,157
cystic fibrosis 30 | 1,670
medulloblastoma 29 | 1,524
pancreatic cancer 29 | 2,300
ductal carcinoma in situ 27 | 1,745
non-small cell lung cancer 27 | 2,798
group 3 medulloblastoma 26 | 2,254
group 4 medulloblastoma 25 | 1,875
ulcerative colitis 25 | 2,087
Cardiomyopathy 23 | 110
adrenocortical carcinoma 23 | 1,427
astrocytoma 23 | 1,493
breast carcinoma 23 | 1,614
diabetes mellitus 23 | 1,663
sonic hedgehog group medulloblastoma 23 | 1,482
Epilepsy 22 | 346
Heart disease 22 | 279
Cancer 21 | 2,346
Duchenne muscular dystrophy 21 | 602
atypical teratoid/rhabdoid tumor 20 | 1,095
interstitial cystitis 20 | 2,299
primary pancreatic ductal adenocarcinoma 20 | 1,271
Dilated cardiomyopathy 19 | 51
Hypertrophic Cardiomyopathy 19 | 56
Long QT syndrome 19 | 53
Myopathy 18 | 128
juvenile dermatomyositis 16 | 1,189
Amyotrophic Lateral Sclerosis 15 | 432
Brugada syndrome 15 | 26
Familial isolated dilated cardiomyopathy 15 | 41
Hypertension 15 | 293
Hypertensive disease 14 | 193
Atopic dermatitis 13 | 944
Distal arthrogryposis 13 | 45
Rheumatoid Arthritis 13 | 1,170
Status Epilepticus 13 | 85
dermatomyositis 13 | 966
fibroadenoma 13 | 557
non primary Sjogren syndrome sicca 13 | 840
tuberculosis 13 | 1,563
Cardiomyopathy, Hypertrophic, Familial 12 | 21
autosomal dominant Emery-Dreifuss muscular dystrophy 12 | 499
posterior fossa group B ependymoma 12 | 1,530
Becker muscular dystrophy 11 | 187
Cardiomyopathy, Dilated 11 | 47
Familial atrial fibrillation 11 | 16
Life-Threatening Ventricular Tachycardia 11 | 15
Primary cutaneous amyloidosis 11 | 26
Short QT syndrome 11 | 12
Cough 10 | 21
Dysuria 10 | 24
Epilepsy characterized by intractable complex partial seizures 10 | 28
Heart conduction disease 10 | 65
Itching of skin 10 | 19
Lennox-Gastaut syndrome 10 | 34
Local anesthesia 10 | 40
Localization-related epilepsy 10 | 13
Minor Skin Wound Pain 10 | 12
Motor cortex epilepsy 10 | 10
Partial seizure 10 | 15
Prevent Minor Bacterial Skin Infection 10 | 10
Skin irritation 10 | 12
Sore throat symptom 10 | 12
Suppression of the Gag Reflex 10 | 12
Tinea pedis 10 | 30
Tonic-clonic epilepsy 10 | 47
Urinary Tract Irritation 10 | 24
Ventricular arrhythmia 10 | 14
aldosterone-producing adenoma 10 | 664
pancreatic ductal adenocarcinoma liver metastasis 10 | 1,795
spina bifida 10 | 1,064

Tissue

Nervous System 197 | 18,560
Female tissues 196 | 18,646
Cardiovascular System 195 | 17,957
Digestive Tract 195 | 18,472
Endocrine System 195 | 18,511
Liver and Pancreas 195 | 18,135
Urinary Tract 195 | 18,443
Blood and immune system 193 | 17,994
Male tissues 193 | 17,968
Skin and soft tissues 192 | 18,114
Respiratory system 191 | 17,483

Target Family

Ion Channel 81 | 341
Non-IDG 75 | 11,969
Transporter 18 | 473
Kinase 12 | 634
Enzyme 7 | 4,146
Transcription Factor 3 | 1,400
Epigenetic 1 | 242

Reactome Pathway

Muscle contraction 197 | 197
Signal Transduction 2,515 | 2,515
Immune System 2,183 | 2,183
Metabolism 2,131 | 2,131
Gene Expression 1,754 | 1,754
Metabolism of proteins 1,544 | 1,544
Innate Immune System 1,375 | 1,375
Signaling by GPCR 1,329 | 1,329
Developmental Biology 1,028 | 1,028
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,004 | 1,004
Adaptive Immune System 938 | 938
Disease 855 | 855
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 803 | 803
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 668 | 668
Membrane Trafficking 608 | 608
Cell Cycle 572 | 572
Neutrophil degranulation 542 | 542
Axon guidance 541 | 541
Signaling by Interleukins 500 | 500
Cell Cycle, Mitotic 470 | 470
Signalling by NGF 467 | 467
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 435 | 435
Class I MHC mediated antigen p... 430 | 430
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 423 | 423
Cellular responses to stress 415 | 415
DAP12 interactions 409 | 409
Infectious disease 391 | 391
NGF signalling via TRKA from t... 378 | 378
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 367 | 367
Diseases of signal transductio... 359 | 359
Transcriptional Regulation by ... 356 | 356
Signaling by EGFR 355 | 355
Metabolism of amino acids and ... 353 | 353
DAP12 signaling 346 | 346
Downstream signal transduction 343 | 343
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 329 | 329
Signaling by SCF-KIT 327 | 327
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 321 | 321
FCERI mediated MAPK activation 316 | 316
Signaling by Insulin receptor 312 | 312
Antigen processing: Ubiquitina... 301 | 301
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 290 | 290
Signaling by Wnt 290 | 290
IGF1R signaling cascade 289 | 289
IRS-related events triggered b... 289 | 289
Insulin receptor signalling ca... 288 | 288
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 285 | 285
MAPK family signaling cascades 283 | 283
Asparagine N-linked glycosylat... 282 | 282
Signaling by the B Cell Recept... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 277 | 277
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 268 | 268
M Phase 266 | 266
Interleukin-3, 5 and GM-CSF si... 262 | 262
RET signaling 261 | 261
Signalling to ERKs 254 | 254
Interleukin-2 signaling 253 | 253
Immunoregulatory interactions ... 252 | 252
RHO GTPase Effectors 249 | 249
VEGFR2 mediated cell prolifera... 249 | 249
Signalling to RAS 247 | 247
Interleukin receptor SHC signa... 246 | 246
G alpha (i) signalling events 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Signaling by Leptin 244 | 244
Prolonged ERK activation event... 243 | 243
MAPK1/MAPK3 signaling 242 | 242
Frs2-mediated activation 241 | 241
HIV Infection 241 | 241
ARMS-mediated activation 240 | 240
Signalling to p38 via RIT and ... 240 | 240
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 236 | 236
RAF/MAP kinase cascade 236 | 236
SHC1 events in EGFR signaling 236 | 236
SOS-mediated signalling 236 | 236
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Phospholipid metabolism 202 | 202

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2 Tbio Transporter -2.85874 681.4 264
Myosin light chain 1/3, skeletal muscle isoform MYL1 Tbio Non-IDG -2.09889 127.4 77
Sodium/potassium-transporting ATPase subunit beta-3 ATP1B3 Tclin Transporter -1.08214 10.9 189
Potassium channel subfamily K member 7 KCNK7 Tdark Ion Channel -0.11301 1.17 17
Potassium voltage-gated channel subfamily H member 2 KCNH2 Tclin Ion Channel -3.19173 1625.2 221
Potassium channel subfamily K member 17 KCNK17 Tbio Ion Channel -1.68499 47.4 29
Potassium channel subfamily K member 16 KCNK16 Tdark Ion Channel -0.80937 5.88 10
Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C Tclin Ion Channel -2.72211 489.2 316
Kv channel-interacting protein 1 KCNIP1 Tbio Ion Channel -1.48426 31.4 205
Sodium/potassium-transporting ATPase subunit beta-2 ATP1B2 Tclin Transporter -1.33849 19.3 155